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p75NTR p75 neurotrophin 
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RNCM Rat Neonatal 
Cardiomyocytes 
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Trk Tropomyosin-related 
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Introduction 
 
Myocardial infarction 
 
Myocardial infarction (MI) is the leading cause of death in the 
United States as well as in most developed countries throughout the 
world.1, 2 According to the American Heart Association, around 13 
million people suffer some form of coronary artery diseases in the 
United States.3 More than 50% of death in Europe in 2001 has been 
related to cardiovascular diseases, and the 80% of these events 
were associated with ischemic conditions.4  
The pathological substrate of MI is atherosclerosis, a chronic 
inflammatory disorder of the artery wall characterized by the 
accumulation of cholesterol in the artery wall. Several risk factors 
predispose to MI. They include aging, hyperglycemia (diabetes), 
dyslipidemia, cigarette smoking, hypertension, obesity, male gender 
and genetic predisposition.5, 6 
These risk factors can promote the occurrence of MI by 
triggering atherosclerosis or aggravating its progression, therefore 
increasing the possibility of accumulating cholesterol and fibrous 
tissue which are essential for the formation of atherosclerotic 
plaques in the inner lining of a coronary artery.  
The coronary vascular system functions as main supplier of 
oxygen and nutrition for the heart tissue, and as transportation 
system for waste products from the underlying heart tissue, i.e. the 
myocardium. 
MI occurs as the consequence of occlusion of one of the 
branches of the coronary artery system, which is caused by the 
sudden disruption of an atherosclerotic plaque that prevents blood 
flow supply to a part of the heart. Once a coronary artery is occluded, 
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a region of the myocardium is deprived of oxygen and nutrition, 
which results in myocardial ischemia (Figure 1). As result, ischemia 
leads to the death of heart muscle. 
 
 
Figure 1.  Schematic example of myocardial infarction 
 
 
 
The angiogenesis process 
 
Angiogenesis is a general term for describing the process of 
growth of new vessels. In the past, the term angiogenesis was used 
to describe the growth of endothelial sprouts from pre-existing post-
capillary venules.7 More recently, this term has been used to 
indicate the growth and remodeling process of the primitive vascular 
network into a complex network.  
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There are three modes that contribute to the process: 
vasculogenesis, angiogenesis (true angiogenesis) and 
arteriogenesis. 
Vasculogenesis is the de novo formation of blood vessels 
starting from endothelial progenitor cells (EPC). It is a crucial 
process for embryonic development, but it has also been considered 
to contribute to vessel growth in adult.8-10 In the adult, EPC originate 
from the bone marrow. 
Angiogenesis is defined as a process by which new blood 
capillaries grow from pre-existing vessels. It plays an important role 
during embryonal development and it is also involved in adult life in 
both physiological and pathological condition, like tumor and chronic 
inflammation.11 
Arteriogenesis is the maturation of capillaries or arterioles and 
the formation of arteriole collaterals.7, 12-15 
 
During embryogenesis, mesoderm-derived cells differentiate 
into endothelial precursors, like EPC and angioblasts, and 
aggregate to form the so called blood islands. Fusion of blood 
islands leads to the formation of primary capillary plexi, the primitive 
and uniform vascular structures, that are remodeled to develop into 
a network of arteries, capillaries and veins. Other cell types 
participate to the process, like vascular smooth-muscle cells that 
associate with arteries and veins, and pericytes that cover capillaries 
making a direct contact with endothelial cells and stabilizing the 
vascular network. 
Similar remodeling processes are thought to be important for 
the formation of blood vessels in both development and 
angiogenesis in adult life. 
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It is now accepted that there are at least two different types of 
angiogenesis: sprouting angiogenesis, that consists in the true 
sprouting of capillaries from pre-existing vessels, and non-sprouting 
angiogenesis like intussusception.16 
Sprouting angiogenesis is a complex process that involves 
many types of cells, growth factors and signaling pathways. It is 
initiated by activation of endothelial cells and vasodilatation of the 
vessel, a process that involves nitric oxide, followed by increased 
vascular permeability. The increase in vascular permeability allows 
extravasation of plasma proteins that provide a stimulus for 
endothelial cells migration. Several proteases, like matrix 
metalloproteinases (MMPs), chymase or plasminogen activator, 
participate to the process by degrading the extracellular matrix and 
by activating growth factors like the vascular endothelial growth 
factor-A (VEGF-A) and fibroblast growth factors (FGFs). The 
degradation of the extracellular matrix allows the endothelial cells to 
migrate to the sites where new capillaries are needed and to 
proliferate, leading to the formation of a lumen and functional 
maturation of the endothelium. Recruitment of pericytes and 
deposition of new extracellular matrix into the subendothelial 
basement membrane promote vessel maturation and quiescence, 
stabilizing the new vascular connection (Figure 2a). 
 
The best characterized type of non-sprouting angiogenesis is 
intussusception, which was first described in the pulmonary capillary 
network.17, 18 
In this process, the opposing microvascular walls protrude into 
the capillary lumen creating a contact zone between endothelial 
cells. The endothelial bilayer is perforated, intracellular contacts are 
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recognized and a transluminal pillar with an interstitial core is 
formed. The core is invaded by interstitial cells leading to its rapid 
enlargement through deposition of collagen fibrils.19 An important 
advantage of intussusception capillary growth is that it permits a 
rapid expansion of the capillary network (Figure 2b). 
 
 
Figure 2.  Sprouting angiogenesis and intussusception 
a.) During sprouting angiogenesis, once activated, EC migrate and proliferate leading 
to the formation of a lumen. Fusion processes at the interfaces between EC cells 
establish a continuous lumen. The final step requires also other cells type like pericytes 
that stabilize the new vascular connection. b.) Intussusception is the splitting of a 
vessel through the insertion of tissue pillars. This process requires also EC proliferation 
and their final contact with pericytes for the stabilization of the endothelium. 
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The driving force of angiogenesis is hypoxia in the surrounding 
tissue. Sprouting of capillaries leads to an increase of their density 
improving blood perfusion of hypoxic tissue which is necessary to 
maintain or restore local oxygen and nutrition supply.14 
Myocardial infarction per se provides a potent stimulus to 
angiogenesis and the subsequent development of collateral 
vasculature that in part maintains and/or revitalizes cardiac tissue.20-
22
  
 
 
EPC and their implication in angiogenesis 
 
EPC are bone marrow-derived cells that circulate in the blood 
and have the ability to differentiate into endothelial cells. Numerous 
studies have demonstrated that EPC can be mobilized from the 
bone marrow into the peripheral circulation after various stimuli, like 
cytokines, growth factors, hormones and tissue injury, including MI. 
 
The mobilization and differentiation of bone marrow–derived 
EPC has been shown to be important in the process of adult 
neovascularization.8, 9, 23, 24  
In animal model of ischemia, EPC were shown to incorporate 
into sites of active neovascularisation in ischemic tissue. After 
transplantation of human peripheral blood-25 or bone marrow-derived 
EPC,26 blood flow recovery and capillary density were markedly 
improved and the rate of limb loss was significantly reduced. 
Improved neovascularisation was also noticed after infusion of 
peripheral blood–derived EPC or implantation of bone marrow 
mononuclear cells after myocardial infarction.27,28 These findings 
provide evidence that exogenously administered EPC can augment 
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naturally occurring neovascularisation in animal models of 
experimentally induced ischemia.29 
Moreover, transplantation of EPC into patients has been 
demonstrated to induce blood flow recovery in ischemic limbs30 and 
increase myocardial left ventricular ejection fraction after myocardial 
infarction.29, 31-34 
 The number and migratory activity of circulating EPC has also 
been shown to inversely correlate with risk factors for coronary 
artery disease35 and to serve as a surrogate biological marker for 
vascular function and cumulative cardiovascular risk.36 
 
The mechanism of EPC-induced neovascularisation is still a 
matter of debate. Several studies showed that bone marrow–derived 
cells incorporate into the newly formed capillaries and express 
endothelial markers, suggesting that EPC enhance 
neovascularisation by physically contributing to the newly formed 
capillaries.  
However, some studies speculate that paracrine effects are 
responsible for the pro-angiogenic effects of EPC. It has been shown 
that bone marrow-derived cells have the ability to secrete potent 
angiogenic ligands (like FGFs, VEGF-A and Angiopoietin-1) as well 
as to be incorporated in the site of neovascularisation,28 while others 
reported that bone marrow–derived cells were able to support tumor 
neovascularisation and growth without physically building endothelial 
structures.37 
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Figure 3.  Schematic example of bone marrow-derived EPC mobilization and 
homing 
After ischemic injury (1.), a variety of factors, including cytokines and growth factors, 
are produced (2.). These factors can stimulate bone marrow-derived EPC mobilization 
(3.), leading to EPC homing (4.) and incorporation (5.) into the ischemic tissue. 
 
 
 
 
 
Gene therapy and therapeutic angiogenesis 
 
Different treatments are available for patients who show 
symptoms suggesting possible myocardial infarction. First line 
agents are aspirin and nitroglycerin that usually are administered 
immediately after first symptoms. Once the diagnosis of MI is 
confirmed, other pharmacologic agents, like β-blockers and anti-
coagulant, are often given.  
Patients with suspected occlusive thrombosis in a coronary 
artery are candidates for immediate reperfusion therapies with 
thrombolytics, like streptokinase or tissue plasminogen activator 
(tPA). An alternative to thrombolytics is percutaneous coronary 
intervention (PCI), also known as coronary angioplasty. This is an 
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invasive procedure in which a guidewire and balloon catheter is used 
to mechanically compress the thrombus and at the same time deal 
with the underlying stenotic atheromatous plaque.  
When these reperfusion therapies are not successful, another 
alternative could be coronary artery bypass graft surgery (CABG). In 
this invasive surgical procedure, arteries or veins from the patient`s 
body are grafted to the coronary arteries to bypass atherosclerotic 
narrowing and improve blood supply to the coronary circulation. 
 
These treatments can be used to reduce or eliminate the 
symptoms of coronary artery disease, including angina (chest pain), 
dyspnea (shortness of breath) and congestive heart failure, as well 
PCI and CABG can also be used to abort an acute MI. 
Even so, there is a large number of patients who have 
incomplete revascularisation using these available techniques and, 
as a result, many of these patients have residual symptoms of 
myocardial ischemia despite medical therapy.38 
 
However, alternative therapies are emerging for the treatment 
of myocardial infarction and other ischemic diseases, like stem cell 
therapy and gene therapy. In fact, after over a decade of preclinical 
studies and recent clinical trials, gene therapy has been established 
as a potential method to induce therapeutic angiogenesis in patients 
with ischemic cardiovascular disease. 
 
Gene therapy (GT) potentially represents one of the most 
important evolutions in medicine, since it can be used to correct 
genetic defects or to express gene products that can be 
therapeutically useful.  
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GT can be defined as the transfer of nucleic acid to the 
somatic cells of an individual to obtain a specific therapeutic effect.39, 
40
  
One of the most important advantages in the use of gene 
therapy is that the beneficial therapeutic effects can be obtained with 
relatively low doses of the delivered genetic material. Another 
advantage of gene transfer compared to classical pharmacological 
approaches is the possibility to continuously produce endogen 
proteins, and that a single local administration of gene may induce a 
long-term therapeutic effect in the target tissue without systemic 
side-effects. 
 
Two different approaches have been used to deliver DNA to 
cells, namely viral vectors and non-viral vectors. Both have different 
advantages, but also different grade of efficiency and side-effects.  
Viral vectors are very efficient in transfecting their DNA into the 
host cell and the size of DNA they can normally deliver is bigger 
compared to non-viral vectors. The most common used viral vectors 
are retroviruses, lentiviruses, adenoviruses and adeno-associated 
viruses. Even if they have a high transduction rate, their capacity is 
limited. For example, first generation-adenoviral vectors are 
immunogenic, although in adenoviral vectors of the third generation 
all viral encoded genes are removed and thereby they mediate lower 
immune response. Moreover, both adeno-associated viruses and 
lentivirus can integrate into the genome at a random position 
therefore increasing safety risks, such as insertional mutagenesis.  
On the other side, non-viral vectors have no infectious or 
mutagenic capability, but they still have a low efficiency. At the 
moment there are three methods of non-viral DNA transfer, namely 
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naked DNA (in the form of a plasmid), liposomes and molecular 
conjugates.  
Plasmids can be directly injected into the target tissue, for 
example muscle cells41 and, although their low efficiency, numerous 
experimental in vivo studies have demonstrated that the direct 
introduction of plasmid-DNA in the myocardium have no side-effects 
and have an organ specific gene expression.42, 43 
One of the most interesting purpose and possible utilization of 
GT in the cardiovascular field is the application of exogenous genes 
capable for the stimulation of growth of capillary and arteriole 
density, leading to a better perfusion of ischemic limb muscle and 
heart.40, 44-48  
 
Therapeutic angiogenesis holds promises for the cure of 
myocardial ischemia. Experimental evidence indicates that supply-
side delivery of angiogenic growth factors improves the perfusion of 
ischemic heart, seemingly resulting in preservation of cardiac 
function. Accordingly, some controlled clinical trials involving intra-
myocardial gene transfer for short-term expression of VEGF-A and 
FGFs showed sufficient levels of safety and a trend towards 
improved myocardial perfusion exercise and performance.49, 50 The 
primary physiological target of the strategy consists of promoting the 
local growth of capillaries and arteriole collaterals, with preference 
for arteriogenesis that more efficiently compensates for occlusion of 
a medium-size coronary artery. In addition, the optimal agent should 
be capable of preventing cardiomyocyte death, while fostering 
regeneration mechanisms for resuscitation of hibernating 
myocardium in the area at risk. 
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Several factors contribute to the angiogenic process, like 
VEGF, FGF, platelet-derived growth factor (PDGF) and transforming 
growth factors (TGFs). On the contrary, anti-angiogenic molecules 
like angiostatin or endostatin lead to the inhibition of angiogenesis. If 
the vessel growth is dysregulated, excessive angiogenesis or 
insufficient vessel growth can lead to a variety of diseases, such as 
cancer and retinopathy. 
During the last years, it has been demonstrated that, in 
addition to these “classical“ angiogenic factors, many other 
endogenous peptides play an important regulatory role in 
angiogenesis. These endogenous regulators include erythropoietin 
(EPO), endothelins (ETs), adrenomedullin (AM), adiponectin, 
neuropeptide-Y (NPY), vasoactive intestinal peptide (VIP), 
substance-P (SP), tissue kallikrein (TK) and neurotrophins such as 
nerve growth factor (NGF).51, 52 
 
Table 1 shows a list of factors implicated in angiogenesis. 
 
GROWTH 
FACTORS 
CHEMOKINES TRANSCRIPTION 
FACTORS 
OTHERS 
VEGF-A, B,C,D,E 
FGF-1,2,4,5 
Angiopoietin-1,2 
HGF, PDGF 
IGF-1,2 
Neurotrophins 
MCP-1 
 
 
 
 
 
HIF-1α 
EGR-1 
Prox-1 
 
 
 
Del-1 
PR39 
Tissue 
kallikrein 
eNOS 
iNOS 
 
 
Table 1.  Factors with known angiogenic properties 
Modified from Ylä-Herttuala S. & Alitalo K., Nat Med. 2003 Jun;9(6):694-701 
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Neurotrophins and their receptors 
 
Neurotrophins (NTs) are secreted molecules responsible for 
numerous functions in the development, differentiation and survival 
especially of neurons, although many of them are now known to 
affect other cell type and tissues. 
The history of neurotrophins started 50 years ago when Levi-
Montalcini, Cohen and Hamburger discovered nerve growth factor 
(NGF),53 the prototypical neurotrophin, as a factor required for 
axonal growth. The other neurotrophins, brain-derived neurotrophic 
factor (BDNF),54 neurotrophin-3 (NT-3),55 and neurotrophin-4/5 (NT-
4/5),56 were identified 30 years later. 
 
NGF is a small secreted protein (13.5 KDa) mainly synthesized 
in specific areas of the central nervous system in mammals, 
principally in the cortex, hippocampus and hypothalamus, but also 
from extra-neuronal cells like fibroblast, epithelial cells and cells 
from the endocrine and immuno system.  
  Initially, NGF was considered as a critical molecule implicated 
in the survival and maintenance of sympathetic and sensory 
neurons as well as involved in neuronal regeneration. Recent 
studies have revealed the potential of NGF and other NTs for 
vascular biology and it is now known that NGF contributes to pro-
angiogenic activities and is able to promote endothelial cells survival 
and proliferation.57-61  
 
Previous study from our group showed that NGF promotes 
neovascularisation in a murine model of hind-limb ischemia and in 
diabetic skin wounds.57, 58, 60  
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We demonstrated that the over-expression of NGF is able to 
accelerate the tissue recovery and reperfusion through the 
improvement of angiogenesis and arteriogenesis. We also showed 
that NGF protects endothelial cells and skeletal myocytes from 
apoptosis.57, 58, 60 
 
Neurotrophins mediate their effects through binding to two 
different receptors, the tropomyosin-related kinase (Trk) receptors 
and the p75 neurotrophin receptor (p75NTR).  
The p75NTR belongs to the tumor necrosis factor (TNF) 
superfamily and was the first identified receptor for NGF.62, 63 The 
p75NTR integral membrane protein is the founding member of the 
TNF family of receptors and contains a cysteine-rich domain and a 
cytoplasmic death domain. 
The first Trk receptor was originally discovered as a 
rearrangement of non-muscle tropomyosin and a then unknown 
tyrosine kinase. This tyrosine kinase was referred to as TrkA and 
subsequently identified as a receptor for NGF.64-67 The identification 
of TrkB and TrkC, based on their similarity to TrkA, followed 
thereafter.68 
For a long time, neurotrophins were believed to bind 
preferentially to specific Trk receptors: NGF to TrkA, BDNF and NT-
4/5 to TrkB, and NT-3 to TrkC. However, some promiscuity exists, 
as NT-3 can also bind with lower affinity to TrkA and TrkB receptors 
that contain an additional short insert in the extracellular domain.69-71 
All NTs bind to p75NTR with equal affinity. 
Trk receptors are typical tyrosine kinase receptors, which 
contain an extracellular domain composed of three leucine-rich 
motifs flanked by two cysteine clusters, two immunoglobulin-like C2 
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type domains (Ig-C2), a single transmembrane domain, and a 
cytoplasmic region with a kinase domain. Binding of NTs to Trk 
receptors occurs mainly through the Ig-C2 domains, with the domain 
closer to the transmembrane region playing a more prominent role, 
as described using chimeras between different Trk receptors, 
deletions, and point mutation analyses.72-76 
In addition to ligand binding, the Ig-C2 domains can also 
stabilize the monomeric form of the Trk receptor to prevent 
spontaneous dimerization and activation in the absence of NTs 
(Figure 4).  
 
 
 
 
 
    
 
 
 
 
Figure 4.  Model of TrkA and p75NTR 
activation  
Neurotrophins selectively bind to specific 
TrkA receptors leading to the activation of 
several trasductional pathways. All 
neurotrophins bind with lower affinity to 
p75NTR receptor. MAPK, mitogen-activated 
protein kinase; PI3K, phosphatidylinositol 
3-kinase; PLC-γ, phospholipase C-γ; NF-
kB, nuclear factor-kB; JNK, Jun N-terminal 
kinase. From Chao, M.V., Nat Rev 
Neurosci., 2003 Apr;4(4):299-309. 
 
 20
Neurotrophins signaling mediated by Trk receptors 
 
The signaling pathways activated by NTs through Trk 
receptors result in many neuronal functions, such as cell survival, 
differentiation, dendritic arborization, synapse formation, plasticity, 
axonal growth, and axonal guidance. Binding of NTs to Trk 
receptors leads to dimerization, phosphorylation in trans of the 
receptors, recruitment of different adaptors and enzymes, and 
activation of several signaling pathways (Figure 5).  
 
 
                      
 
 
 
 
 
Figure 5.  TrkA 
receptor signaling 
Several signaling pathway 
can be activated by the 
binding of NTs to Trk 
receptors. Among these, the 
PI3K-Akt, Shc-Ras-MAPK, 
Rap-MAPK, and PLCγ-
protein kinase C (PKC) 
pathways are the most 
known. Adapted from Chao, 
M.V., Nat Rev 
Neurosci.,2003,Apr;4(4):299-
309. 
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These events are shared by other receptor tyrosine kinases, 
but the unique combination of Trk receptor docking sites, 
recruitment of different adaptors and enzymes, and regulated 
receptor trafficking elicits specific responses for NTs. Two tyrosines 
in Trk receptors (Y490 and Y785 in the human TrkA receptor and 
their corresponding tyrosines in TrkB and TrkC receptors) are 
phosphorylated in response to NTs and serve as the major docking 
sites for binding of adaptor proteins and enzymes. Y490 and Y785 
primarily recruit Shc and phospholipase C (PLC), respectively. The 
phosphorylated tyrosines located at the kinase domain, Y670, Y674, 
and Y675, can also engage adaptor proteins, including SH2B, APS, 
and Grb2.77, 78 
Among the signaling pathways activated by Trk receptors in 
response to NTs, the PI3K-Akt, Shc-Ras-MAPK, Rap-MAPK, and 
PLCγ-protein kinase C (PKC) pathways are the most studied. 
 
- PI3K-Akt 
NTs play an important role in the survival of several neuronal 
populations during development, and signaling through the PI3K-Akt 
pathway is critical for this function. However, PI3K/Akt is strongly 
implicated in angiogenesis,79 vasculogenesis80 and survival of 
endothelial cells81 and cardiomyocytes.82, 83 We showed that Akt 
mediates NGF-induced neovascularisation in ischemic limb 
muscles.57  
Active Trk receptors engage Shc, which associates with Grb2 
and Gab1 to activate PI3K and, subsequently, Akt. PI3K binding to 
Gab1 is required for PI3K activation, as disruption of this association 
decreases the NGF-dependent survival of PC12 cells.84  
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Several different pro-apoptotic and pro-survival effectors 
downstream of Akt can mediate the survival actions of NTs. For 
example, Bad phosphorylation by Akt leads to additional 
phosphorylation of Bad by other kinases, which prevents the pro-
apoptotic effects of the protein.85 Similarly, the forkhead transcription 
factor Foxo–3a, which regulates the expression of several pro-
apoptotic proteins, is phosphorylated by Akt in response to NTs, 
thus preventing its transcriptional activity.86 Moreover, the NF-kB 
pro-survival pathway is activated via Akt phosphorylation of its 
inhibitor IkB, which decides for IkB degradation. PI3K-Akt can also 
exert a positive effect on the retrograde signaling that modulates 
neuronal survival.87 
Signaling through PI3K-Akt mediates functions other than 
survival. Active Akt at the growth cone causes axonal growth and 
increases axon caliber and branching in sensory neurons by 
phosphorylating and inactivating glycogen synthase kinase-3β 
(GSK-3β) locally, leading to microtubule assembly that promotes 
axonal growth.88  
Similarly, Akt has been implicated in cardiomyocyte 
hypertrophy. Stimulation and chronic activation of the PI3K-Akt 
pathway by insulin-like growth factor-1 (IGF-1) in the heart, as well 
as over-expression of constitutively active Akt, leads to cardiac 
hypertrophy.89, 90 
Akt phosphorylates substrates including regulators of 
apoptosis and growth in both cytoplasmic and nuclear 
compartments. Inactive Akt is located principally in the cytoplasm. 
During receptor-mediated activation, Akt is recruited to the plasma 
membrane where it undergoes a double phosphorylation involving 
auto-phosphorylation (or phosphorylation by an unidentified kinase) 
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on Ser-473 and by phosphoinositide-dependent kinase-1 (PDK-1) 
on Thr-308.91  Phosphorylated Akt leaves the membrane and targets 
substrates in the cytoplasm and nucleus. Potential cytoplasmic Akt 
targets are GLUT-4,92 the main cardiac glucose transporter, many 
regulators of apoptosis, including Bad and caspase-9, and GSK-
3β93, 94 which, besides its role in both cell cycle and protein synthesis 
regulation, it is also implicated in the Akt-dependent regulation of 
cardiac hypertrophy. In fact, when Akt is chronically situated in the 
cytoplasm it can lead to the phosphorylation/inactivation of GSK-3β 
resulting in cardiac hypertrophy, whereas when Akt is targeted to the 
nuclear compartment, GSK-3β is inaccessible and retains activity 
preventing hypertrophy. 
Potential nuclear targets include the Fas ligand (FasL), Foxo, 
the transcriptional regulator Bcl-6, and the cell cycle regulator 
p27Kip1. 
 
- Ras-MAPK 
Activation of the small GTPase Ras in response to NTs has 
been linked to signaling and transcriptional regulation implicated in 
neuronal survival and differentiation. Ras is induced rapidly, but 
transiently, by NGF in PC12 cells.95 TrkA receptor stimulation by 
NGF engages Shc and Grb2 to activate the GEF SOS, which then 
activates Ras.96 Raf-1 and B-Raf activation downstream of Ras 
subsequently triggers the activation of extracellular signal-regulated 
kinases/mitogen-activated protein kinases (MAPK).97, 98 Stimulation 
of Ras through this pathway promotes only transient activation of 
MAPK.99 Modulation of Ras signaling can be achieved by a negative 
feedback loop, as activation of MAPK can stop the signaling of this 
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pathway by phosphorylating SOS to disrupt the Grb2-SOS 
complex.100 
In recent years, NGF-induced activation of MAPK has been 
also described in endothelial cells. Activation of the Ras/MAPK 
pathway in response to NGF leads to endothelial cells migration.101 
Moreover, the MAPK pathway is responsible of NGF-induced 
endothelial cells proliferation through phosphorylation of TrkA 
followed by phosphorylation of the MAPK ERK1/2.58   
 
- PLCγ 
The first reports indicating that NT actions result in activation of 
PLCγ showed serine, threonine, and tyrosine phosphorylation of 
PLCγ  directly mediated by the Trk receptor kinase. Trk receptor 
phosphorylation at Y785 leads to PLCγ recruitment and activation, 
which results in the hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PtdIns(4,5)P2) to generate inositol tris phosphate 
(IP3) and diacylglycerol (DAG).102 IP3 and DAG cause the activation 
of different PKC isoforms. The effect of IP3 is mediated by release 
of Ca2+ from internal stores that additionally stimulate Ca2+-
calmodulin-regulated protein kinases (CaM kinases). PKC 
subsequently activates the ERK1 signaling pathway via Raf.103 PLCγ 
activation in response to NTs has been implicated in growth cone 
chemotropism and in the potentiation of thermal sensitivity by VR1, 
a heat-activated ion channel on sensory neurons.104, 105 Moreover, 
the prolonged activation of PLCγ by a brief pulse of NGF induces 
transcription of a sodium channel gene.106, 107 
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Aim of the study and experimental design 
Recent studies have demonstrated that therapies designed to 
stimulate neovascularisation can be indicated to counteract ischemic 
diseases.24, 30, 39, 46  
The ability of NGF to promote new vessel growth and 
formation and to inhibit apoptosis has suggested us that NGF could 
have an appropriate therapeutic action for the treatment of 
myocardial infarction.  
The aim of the study was to evaluate the action of NGF on 
cardiomyocytes and EPC and to assess the regional effects of NGF 
gene transfer into the peri-infarct zone of mouse myocardium. We 
studied the characteristics of microvascular remodeling induced by 
NGF in the border and remote zone of the infarcted heart, the 
impact on endothelial cells and cardiomyocytes apoptosis, and the 
long-term influence on cardiac contractility. To characterize NGF 
cellular actions and signaling, a part of the study has been done on 
isolated rat neonatal cardiomyocytes and human EPC. 
 
The major points of this study are the following:  
1. To evaluate the role of NGF on reparative neovascularisation 
in the ischemic heart in vivo. 
2. To investigate the effect of NGF gene transfer treatment on 
cardiomyocyte and endothelial cells survival in vivo. 
3. To evaluate whether NGF delivery to the peri-infarcted heart 
could prevent post-MI heart failure. 
4. To define NGF signaling in the cardiomyocyte in vitro 
5. To assess the role of NGF on EPC proliferation and migration 
in vitro. 
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Materials and Methods 
 
 
Animals 
 
Experiments were performed in male CD1 mice with initial 
body weight between 35 to 40 g (Charles River, Comerio, Italy). 
Procedures complied with the standards stated in the Guide for 
the Care and Use of Laboratory Animals (Institute of Laboratory 
Animal Resources, National Academy of Science, Bethesda, MD, 
1996). Mice were housed under standard conditions (23°C, 12-h 
light/dark cycle) and given free access to water and standard food.  
 
 
Plasmid and adenoviral vector preparation 
 
The pCMV-Sport 6 containing the complete cDNA of human 
NGF-β (p.NGF), cloned into NotI and SalI restriction sites, was 
purchased (LGC Promochem, Teddington, UK).  
To prepare an adenoviral vector carrying human NGF-β 
(Ad.NGF), the coding sequence for the NGF-β from p.NGF was 
amplified (KOD proofreading DNA polymerase, Novagen, 
Darmstadt, Germany) using the following primers:  5’-
GCTAGCGTAATGTCCATGTTGTTCTAC-3’ (NheI site) and 5’-
GGATCCTCTCACAGCCTTCCT-3’  (BamHI site and stop signal 
removed) to allow the inclusion of a V5 tag at the C-terminus.  The 
fragment was excised and subcloned in the shuttle vector pDC515 
(Microbix Biosystems, Toronto, ON, Canada) modified to contain the 
V5 coding sequence. A replication-deficient adenovirus was 
generated by site-specific FLP-mediated recombination of the co-
transfected shuttle and genomic plasmids in 293 cells. Viral stocks 
were amplified, CsCl banded, and titrated.108 
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Myocardial infarction model 
 
Myocardial infarction was performed in CD1 mice anesthetized 
with a combination of ketamine (50mg/kg) and xylazine (2.5mg/kg), 
intubated and artificially ventilated (tidal volume: 8-9µl/g; stroke rate: 
165/min) during the procedure.  
Under a surgical microscope, an incision was made at the left 
fourth intercostal space to expose the heart and MI was induced by 
permanent ligature of the proximal left anterior descending coronary 
artery (LAD) by using a 7.0 Mersilene suture (Ethicon, Somerville, 
NJ, USA). 
Occlusion was confirmed by pallor and regional wall motion 
abnormality of the left ventricle. 
 
 
Gene transfer in vivo 
 
Two minutes after MI, gene transfer was performed 
intramyocardially with multiple injections.  
Under the surgical microscope, we enter the infarct zone using 
a 30G needle bent at the right angle and injected the genetic 
material in 3 equidistant points of the MI border zone. Sham-
operated mice underwent the same procedure except LAD was 
circled with a 7.0 Mersilene suture but not occluded. Surgical wound 
was sutured and animals were allowed to recover. Surgical mortality 
rate was less than 8% in all MI groups. 
 
In the first part of the study, NGF gene transfer was performed 
by using a plasmid carrying the human NGF gene (p.NGF) at the 
dose of 5µg in 10µl of NaCl. Control animals were treated with the 
same dose of an empty vector (p.Null). The capacity of 5µg p.NGF 
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to induce the transgene expression in the mouse infarcted heart was 
assessed by RT-PCR three days after MI by using p.NGF at the 
doses of 5µg, 10µg and 25µg (n=6 animals/group). 
The effect of NGF gene transfer after MI was also analyzed by 
using an adenoviral vector carrying the human NGF in the 
expression cassette. Ad.hNGF was injected in the MI border zone at 
the dose of 107, 108 and 109 p.f.u. (n=6 animals/group). Three days 
after MI and gene transfer, the peri-infarct zone was isolated. The 
dose of 108 p.f.u. for Ad.hNGF was chosen after human NGF 
expression was assessed by RT-PCR. Control animals received the 
same volume of Ad.Null (108 p.f.u.). 
 
 
Histological analyses 
 
Histological analyses were performed after hearts were 
perfusion-fixed and embedded in paraffin three days or two weeks 
after MI.  
Briefly, mice were anaesthetized (2,2,2-tribromoethanol, 
880mmol/kg body weight IP, Sigma Aldrich, Milano, Italy), the 
abdominal cavity was opened and the aorta was cannulated with a 
PE50-catheter connected to a perfusion apparatus. Next, the chest 
was opened and the heart stopped in diastole by left ventricle (LV) 
intracavitary injection of cadmium-chloride (100nmol); the right 
atrium was then opened and the heart was perfused with 
heparinized PBS for 1 minute, followed by 10 minutes with 10% 
buffered formalin at 100mmHg through the abdominal aorta. 
The heart was excised, placed in 4% formalin for 24 hours109 
then the free walls of the right ventricle (RV) and LV inclusive of the 
septum were separated and their weight recorded.  
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Finally, the heart was sliced into four transversal sections of 
which the first section contained the atrio-ventricular level, the 
second section showed the following healthy tissue, the third section 
showed the peri-infarct zone until the middle part of the scar, 
thereby including the LV posterior wall, which belongs to the remote 
zone, and the fourth section showed the apical scar-part of the 
heart. Heart sections of 4 or 5µm thickness were than prepared for 
histological and immuno-histological staining. 
Moreover, LV transversal diameters and wall thickness were 
analyzed with a stereomicroscope connected to a digital camera 
(Kodak, DC290 ZOOM). Captured photographs were analyzed by 
the use of Image-Pro Plus 4.0 software (Media Cybernetics, Silver 
Spring, MD, USA). The cavity volume was calculated with the Dodge 
equation.109, 110 
 
-  Immuno-staining for NGF 
The capacity of NGF gene delivery to produce the transgenic 
protein in the infarcted heart was determined at 14 days post-MI by 
NGF immuno-staining (1:50; Santa Cruz Biotechnology, Santa Cruz, 
CA, USA). 
Immuno-staining for NGF was also performed to determine the 
effect of myocardial infarction on NGF expression. For this purpose, 
a rabbit polyclonal antibody (1:50; Santa Cruz Biotechnology), which 
recognizes both human and murine NGF, has been used. The 
antigen was visualized by incubation with diaminobenzidine 
tetrahydrochloride (DAB) (Dako, Glostrup, Denmark). In negative 
controls the primary antibody was substituted by non immune rabbit 
IgG. Counterstaining was performed with hematoxylin. 
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- Analyses of capillary density 
At 14 days after MI, capillary density following p.NGF gene 
transfer was determined in both peri-infarct and remote myocardium 
following Silver-hexamethylenetetramine staining, which defines 
vascular basal membrane and the cell nucleus.109  
Analysis was performed with an ocular reticle (9604 µm2 area) 
at 1000X magnification. A total of 20 fields were analysed in order to 
compute the capillary numerical density/mm2 of tissue. 
Moreover, capillary density was also assessed after MI and 
gene transfer with the adenoviral vector carrying the human NGF 
(Ad.NGF 108 p.f.u.). Briefly, in deparaffinized and rehydratated 5µm 
thick sections, endothelial cells (EC) were recognized by fluorescent 
immuno-histochemical staining for Factor VIII by using a primary 
rabbit polyclonal antibody (1:100; Dako) and revealed by a FITC-
conjugated goat anti-rabbit secondary antibody (Sigma Aldrich). In 
the same sections, cardiomyocytes were stained for α-sarcomeric 
actin by using a primary mouse antibody (1:20; Dako) and revealed 
by a TRITC-conjugated secondary goat anti-mouse secondary. 
Nuclei were counterstained by DAPI. Slides were observed under a 
fluorescence microscope. High power fields were captured (at 400X) 
from Ad.NGF and Ad.Null hearts and the number of capillaries per 
field was counted in blind.  
 
- Evaluation of apoptosis 
Two weeks after MI and gene transfer, apoptosis was 
analyzed by TUNEL assay on 4µm LV sections. Cardiomyocytes 
were recognized by α-sarcomeric actin (1:30; Dako), and revealed 
by VIP kit (Vector Laboratories, Burlingame, CA, USA). In separate 
heart sections, endothelial cells were identified by staining for Factor 
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VIII (1:20; Dako), and revealed by VIP kit. The numbers of TUNEL-
positive apoptotic cardiomyocytes and TUNEL-positive apoptotic EC 
were separately counted in the peri-infarct myocardium with the aid 
of ocular reticle (at 1000X). The density of apoptotic cardiomyocytes 
and apoptotic endothelial cells was calculated per mm2 of tissue 
section111. 
 
 
Hemodynamic parameters and heart remodeling 
 
Cardiac function and dimensions were performed in artificially 
ventilated mice under Thiopental anesthesia (125mg/kg body 
weight) at 5 weeks after MI. Left ventricular catheterization has been 
performed using a high-fidelity micro-tip pressure transducer (1.4F 
Millar-Micro-Tip catheter, Millar Instruments, Houston, TX, USA). 
The catheter was inserted into the right carotid artery and 
moved on until the left ventricular cavity. Heart rate (HR, bpm), peak 
systolic LV pressure (LVP, mmHg), maximal rate of LV pressure rise 
(dP/dtmax, mmHg/s) and fall (dP/dtmin, mmHg/s) were digitally 
recorded and analyzed using a Power-Lab/4SP polygraph (AD 
Instruments, Colorado Springs, CO, USA).  
After intraventricular pressure measurements, hearts were 
stopped in diastole by intracardiac injection of cadmium chloride 
(100nM). The heart was excised and separated in LV (including 
septum) and right ventricle (RV) and the following parameters were 
analyzed: total heart weight (HW) to body weight (BW) ratio, LVW to 
BW, RVW to BW, LV free wall thickness and LV transversal 
diameter and volume.  
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Rat neonatal cardiomyocytes isolation 
 
To better understand the effects of NGF and its pro-survival 
and anti-apoptotic features, we decided to analyse the role of NGF 
in rat neonatal cardiomyocytes (RNCMs) in vitro. 
Hearts from neonatal Wistar rats (Charles River) were rapidly 
excised and washed to remove blood and debris. The whole heart 
was carefully minced and submitted to four cycles of digestion in 
0.1% trypsin containing 0.02% EDTA in PBS at 37°C w ith gently 
stirring. Digestion was stopped by adding 20% fetal calf serum 
(FCS). The dispersed cells were resuspended in MEM 
supplemented with 10% FCS, 100µg/ml streptomycin, and 100U/ml 
penicillin and preplated for 1 hour to allow the adhesion of fibroblasts 
leaving the myocytes in suspension. The suspended 
cardiomyocytes were resuspended in EMEM with 10% FCS, 
counted and cultured in 6 well plates previously coated with 1% 
gelatin in PBS at the density of 106 myocytes/well.  After 24 hours in 
culture, the culture medium was replaced to 4:1 DMEM-M199, 
containing antibiotics and 1% FCS, and the cells were kept in culture 
until they were used for experiments. 
 
 
Immunocytochemical analyses of rat neonatal 
cardiomyocytes 
 
After isolation, rat neonatal cardiomyocytes were cultured in 
gelatine-coated Labtekt slides (Nalge Nunc Int., Rochester, NY, 
USA), fixed with 4% paraformaldehyde (PFA, 10min, RT) and 
permeabilized (0.2% Triton X-100 in PBS, 20min, RT). After blocking 
with 5% normal goat serum (1h, RT), cells were incubated with the 
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following primary antibodies (16h, 4°C): α-sarcomeric actin (1:50; 
DAKO) and NGF (1:50; Santa Cruz Biotechnology). 
This was followed by incubation (1h, RT) with rabbit anti-
mouse PE conjugated secondary antibody (1:200; Sigma-Aldrich) or 
goat anti-rabbit Alexas-Green 488-conjugated secondary antibody 
(1:200; Molecular Probes, Paisley, UK). In negative controls, the 
primary antibody was substituted with non-immune IgG. Coverslips 
were mounted using Vectashields (Vector Laboratories) mounting 
medium containing 4’.6 diamidino-2 phenyindole (DAPI) or 
propidium iodide (PI). Cells were observed under a fluorescence 
microscope (Olympus BX40, Southall, UK). 
 
 
RNA extraction and RT-PCR 
 
Gene expression was assessed by reverse transcription-
polymerase chain reaction (RT-PCR) in both hearts isolated from 
infarcted animals and rat neonatal cardiomyocytes. 
 
- RT-PCR on infarcted heart 
Three days after MI, the heart of anaesthetized mice was 
harvested and processed for RNA extraction. Total RNA was 
isolated from each heart of mice and one microgram of synthesized 
complementary DNA (cDNA) was prepared for the measurements. 
Total RNA was isolated with an RNeasy Kit from Qiagen 
(Qiagen, Valencia, CA, USA). Briefly, tissues were homogenized in 
Trizol using a rotor-stator homogenizer. The homogenates were 
further centrifuged and the supernatants were precipitated with 
ethanol and the mixture was applied to a RNeasy mini spin column 
for adsorption of RNA to a membrane. The RNA bound to the 
membrane after centrifuging for 15 seconds at 10.000 rpm. After 
 34
digestion with DNase-I to eliminate DNA contamination, the total 
ready-use RNA was eluted with RNase-free water and was stored at 
–80°C. The concentration of the sample was determin ed using a 
DNA/RNA reader and the quality of RNA was evaluated by 
A260/A280 value. 
One microgram of total RNA was used to synthesize cDNA in 
a reaction mixture in a volume of 20µl which contained 200 units of 
M-MLV reverse transcriptase in the presence of 1X first–strand 
buffer, 5ng/µl random primers, 10mM dithiothreitol, 500µM dNTPs, 
and 2 units/µl of Rnasin Recombinant Ribonuclease Inhibitor. The 
reaction was carried out in a 0.5 ml eppendorf tube at 25 °C for 10 
minutes, followed by 37 °C for 50 minutes. After re action, the tube 
was heated at 70 °C for 15 minutes to inactivate th e enzyme and to 
stop the reaction.  
The following set of primers has been used: human NGF-ß, 
forward: 5’-GGCTGCCTGGCGGTTTAT-3’, and reverse: 5’-
GGCAGGTCAGGCTCTTCTCA-3’, which amplify human NGF cDNA 
but do not amplify murine NGF cDNA; mouse NGF-ß: forward:5’-
AGACTTCCAGGCCCATGGTA-3’, reverse: 5’-GAACTCCCC 
CATGTGGAAGA-3’; mouse TrkA: forward: 5’-CTTTGTGCAC 
CGGGATCTG-3’, reverse: 5’-TCATGCCAAAGTCTCCA-ATCTTC-3’) 
and normalized towards murine GAPDH57 (Table 2). 
 
- RT-PCR on rat neonatal cardiomyocytes 
Rat neonatal cardiomyocyte total RNA was extracted using 
RNAeasy mini kit (Qiagen). First-strand cDNA was synthesized from 
1mg of total RNA using 200U of Moloney–murine leukemia virus 
reverse transcriptase (Invitrogen Ltd, Paisley, UK) and oligo-dT 
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oligomer (Invitrogen) as primer. One microliter of each cDNA 
preparation was amplified by PCR.  
The following forward and reverse oligonucleotides were used: 
rat NGF-ß, forward, 5'-CTTCAGCATTCCCTTGACAC-3'; and 
reverse, 5'-TGAGCACACACACGCAGGC-3',  human NGF-ß 5’-
GGCTGCCTGGCGGTTTAT-3’, and reverse: 5’-GGCAGGTCAG 
GCTCTTCTCA-3’ (primers amplify human NGF cDNA but do not 
amplify rat NGF cDNA), rat TrkA, forward, 5'-GCATCCTCT 
TACCGCAAGTT-3', and reverse 5'- CAGACTCCTAGCCC 
CAGAACG-3'; 18S rRNA forward, 5'-TAGAGGGACAAGTG 
GCGTTC-3', and reverse 5'-TGTACAAAGGGCAGGGACTT-3' 
(Table 2). 
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cDNA 
 
Sequence 
human NGF-β forward 
reverse 
probe size 
5’-GGCTGCCTGGCGGTTTAT-3’ 
5’-GGCAGGTCAGGCTCTTCTCA-3’ 
192bp 
primers amplify human NGF cDNA but not 
rat NGF cDNA 
mouse NGF-ß forward 
reverse 
probe size 
5’-AGACTTCCAGGCCCATGGTA-3’ 
5’-GAACTCCCCCATGTGGAAGA-3’ 
412bp 
rat NGF-β forward 
reverse 
probe size 
5’-CTTCAGCATTCCCTTGACAC-3’ 
5’-TGAGCACACACACGCAGGC-3’ 
592bp 
mouse TrkA forward 
reverse 
probe size 
5’-CTTTGTGCACCGGGATCTG-3’ 
5’-TCATGCCAAAGTCTCCAATCTTC-3’ 
434bp 
rat TrkA forward 
reverse 
probe size 
5’-GCATCCTCTTACCGCAAGTT-3’ 
5’-CAGACTCCTAGCCCCAGAACG-3’ 
306bp 
18S rRNA forward 
reverse 
5’-TAGAGGGACAAGTGGCGTTC-3’ 
5’-TGTACAAAGGGCAGGGACTT-3’ 
 
Table 2.  Sequences of primers used for RT-PCR  
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Protein level quantification and western blot 
analyses 
 
- Western blot analyse of infarcted heart 
Tissue samples of the peri-infarct zone were homogenized in 
600µl of ice-cold protein extraction buffer using a rotor-stator 
homogenizer. The buffer for homogenization contained 200mmol/l 
sucrose, 20mmol/l Hepes buffer [pH 7.4] and protease inhibitors. 
After incubation at 4°C for 30 minutes, the homogen ate was 
centrifuged at 10.000 rpm for 10 minutes at 4°C. Th e pellet was 
discarded and the supernatant was collected and frozen at –80°C. 
The concentration of protein in the supernatant was determined by 
the method of Bradford. An equal amount of protein was loaded into 
a 10% SDS-polyacrylamide gel and subsequently blotted onto a 
PVDF membrane (Bio-rad, Hercules, CA, USA). Antibodies against 
phospho-Akt-B (Ser-473) and Akt-B (Cell Signaling) were used at a 
dilution of 1:1000, phospho-eNOS (Ser-1177) (Cell Signaling, 
Danvers, MA, USA) and eNOS (Cell Signaling) were used at a 
dilution of 1:500 and 1:1000 respectively. Specific protein was 
detected by chemiluminescent reaction (ECL kit, Amersham 
Biosciences, Little Chalfont, UK) followed by exposure of the 
membrane to Hyperfilm™ MP (Amersham Biosciences). 
Quantifications were performed by densitometric analysis after 
scanning using the software Scion Image 4.0 (Scion Corporation, 
Frederick, MA, USA). The ratio of phosphorilated to total Akt-B and 
phosphorylated to total eNOS was calculated. 
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- Western blot analyses of rat neonatal cardiomyocytes 
Serum-starved RNCM were treated with NGF (50ng/ml) before 
undergoing protein extraction. Some cells were also pre-treated with 
the TrkA inhibitor K252a (100nM) or the PI3K inhibitor LY294002 
(50nM).  
Protein extraction from RNCM was carried out using ice-cold 
RIPA buffer (Pierce, Rockford, IL, USA) with protease inhibitors at 
time 0 and after 10, 20, and 60 min of NGF or combined treatments. 
Cells were kept in the lysis buffer for 30 minutes at 4°C before being 
centrifuged at 12.000 rpm for 10 minutes at 4°C. Th e supernatant 
was collected and frozen at –80°C. Protein concentr ation was 
defined by the method of Bradford. Proteins were separated in 10% 
SDS-polyacrylamide gels and blotted into a PVDF membrane (Bio-
rad). The following antibodies were used: phospho-TrkA (Tyr-490), 
total TrkA, phospho-Akt (Ser-473), total Akt, phospho-Foxo-3a (Thr-
32), total Foxo-3a, phospho-Foxo-1 (Ser-256) and total Foxo-1(all 
from Cell Signaling; dilution at 1:1000). 
Proteins were detected by ECL chemiluminescent reaction 
(Amersham Biosciences) and quantified by densitometric analysis 
after scanning using the software Scion Image 4.0 (Scion 
Corporation). The ratio of phosphorylated to total form was 
calculated. 
 
 
ELISA 
 
Serum-free conditioned culture medium of rat neonatal 
cardiomyocytes was used to investigate RNCM-released NGF 
content by the NGF Emax® ImmunoAssay System (Promega, 
Madison, WI, USA). RNCM were maintained in serum-free medium 
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for 24 hours before collecting the conditioned medium. ELISA assay 
was performed according to the manufacture instructions.  
 
 
Hypoxia/reoxygenation and Angiotensin II 
apoptosis assays on rat neonatal cardiomyocytes 
 
RNCM were submitted to hypoxia/reoxygenation (H/R) or 
incubated with Angiotensin II (Ang II), two conditions which 
reportedly cause cardiomyocyte apoptosis. 
 
- Hypoxia/reoxygenation assay 
Rat neonatal cardiomyocytes were infected overnight with 
Ad.hNGF or Ad.βGal (50M.O.I. each). Cells were then transferred to 
an anaerobic chamber which was purged with 95% N2/5% CO2. 
RNCM were kept under hypoxia for 12 hours before being 
reoxygenated under normoxic conditions for 24 hours. Incubations 
were performed at 37°C. Normoxic condition was used  as control. 
Apoptosis was detected by cleaved caspase-3 immuno-staining and 
confirmed by TUNEL assay. 
 
- Angiotensin II apoptosis assay 
After overnight infection with Ad.hNGF or Ad.βGal (50 M.O.I. 
each), RNCM were incubated with AngII (10-7 M) for 24 hours at 
37°C. PBS was used as control. 
Apoptosis was then detected by cleaved caspase-3 immuno-
staining. 
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Human EPC culture 
 
To prepare EPC, mononuclear cells (MNCs) were isolated by 
Biocoll density-gradient centrifugation with Histopaque 1077 (Sigma 
Aldrich) from 20ml of human peripheral blood of healthy volunteers. 
After separation, cells were washed two times in phosphate buffered 
saline (PBS) and counted. Peripheral blood-MNCs were suspended 
in EPC culture medium EGM-2-MV (Cambrex, Milano, Italy) 
supplemented with 10% FBS, hEGF, hydrocortisone, GA-1000, 
VEGF, hFGF-B, IGF-1 and ascorbic acid (all from Cambrex) and 
plated on 10µg/ml human fibronectin-coated tissue culture plates. 
After 4 days non-adherent cells were removed and fresh medium 
was added to the adherent EPC. When necessary, EPC were 
detached with trypsin, counted and subjected to experiments.  
 
 
EPC migration assay 
 
After 4 days in culture, isolated EPC were washed in PBS (pH 
7.4), detached using trypsin for 2 minutes at 37°C.  after washing 
and centrifugation, cells were resuspended in EBM-2 with 0.1% 
bovine serum albumin (BSA), counted, and 5x104 cells were placed 
in 150µL of EBM-2 with 0.1% BSA in the upper chamber of a 
modified Boyden chamber (Costar Transwell, Corning Incorporated, 
Acton, MA, USA) composed by a 5µm-pores polycarbonate 
membrane of which the lower surface was pre-coated with 
fibronectin (10µg/ml, Sigma Aldrich). The chamber was placed in a 
24-well culture dish containing EBM-2 (in 0.1%BSA) and human 
recombinant NGF at different concentration (10ng/ml, 50ng/ml and 
100ng/ml). Human recombinant SDF-1 (100ng/ml, R&D System) 
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was used as positive control for migration while EBM-2 in 0.1% BSA 
as a negative control. 
 
After overnight incubation in a humidified incubator at 37°C, 
non-migrated cells were removed from the upper chamber by gently 
wiping the upper surface of the membrane with a cotton swab, the 
membrane was isolated and washed with PBS, fixed with methanol 
and placed on a slide mounted with DAPI-Vectashield (Vector 
Laboratories). Migrating cells into the lower chamber were counted 
using a fluorescent microscope in 5 random microscopic fields at 
20X magnification. Each experiment was performed in triplicate. 
Evaluations were performed in blind. 
 
 
MTS cell proliferation assay 
 
After 7 days in culture, isolated EPC were washed in PBS and 
detached with trypsin (2 minutes at 37°C). Cells we re counted and 
cultured at the density of 1x104 cells/well in a flat bottomed 96 well 
plate and stimulated with different doses of NGF (NGF 5ng/ml; NGF 
50ng/ml; NGF 100ng/ml) for 24 hours. The viability of cell cultures 
was monitored over time by [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium (MTS) 
colorimetric assay following the manufacturer’s instructions 
(CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay, 
Promega, Milano, Italy). Cell viability was determined by measuring 
the absorbance at 490 nm using a 550 BioRad plate-reader (Bio-
Rad). 
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Statistical analyses 
 
Values are presented as mean±SEM. Statistical significance 
was evaluated through the use of an unpaired t test for comparisons 
between 2 groups. For comparison among more than 2 groups, 
ANOVA was used, followed by an unpaired t test to compare 2 
groups within them. Analyses were performed using the SigmaStat 
3.1 software. A P value <0.05 was interpreted to denote statistical 
significance. 
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Results 
 
 
NGF and TrkA expression after myocardial 
infarction 
 
Myocardial infarction increased the cardiac levels of NGF. 
Immuno-staining for NGF revealed a higher endogenous NGF 
protein content in the heart of infarcted animals in comparison to 
sham-operated. Figure 6 shows that sham-operated hearts express 
low levels of NGF, and the expression of murine NGF increased 
following myocardial infarction.  
 
 
 
Figure 6.  NGF protein content after myocardial infarction  
Myocardial infarction or sham operation was induced in mice. NGF protein content 
was revealed by immuno-histochemistry using an antibody which recognizes both 
human and murine NGF. Counterstaining was performed with hematoxylin 
(Magnification 200X). 
 
 
 
 
 
 
Sham MI 
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Moreover, the analyses of mRNA levels by RT-PCR confirmed 
an increase of both NGF (NGF/GAPDH cDNA level ratio multiplied 
per 100: 0.410±0.052 vs. 0.068±0.016 in sham-operation, P<0.05) 
and TrkA (TrkA/GAPDH cDNA level ratio multiplied per 100: 
0.190±0.023 vs. 0.029±0.005 in sham-operation, P<0.05) content in 
heart submitted to myocardial infarction (Figure 7).  
 
Figure 7.  NGF and TrkA mRNA expression after myocardial infarction  
Bar graphs showing the ratio between NGF to GAPDH (left panel) and TrkA to GAPDH 
(right panel) mRNA expression levels determined in the peri-infact zone at 3 days post-
MI. Data are expressed as mean±SEM (n=5/group). *P<0.05 vs. sham. 
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NGF transgene expression after myocardial infarction and 
plasmid-mediated gene transfer 
 
Intra-myocardial p.NGF delivery induced expression of human 
NGF mRNA (Figure 8) and increase the content of total (murine plus 
human) NGF protein in comparison to p.Null in the peri-infarct 
myocardium (Figure 9). 
 
 
Figure 8.  NGF mRNA levels after myocardial infarction and plasmid-mediated 
gene transfer  
Bar graphs showing the mRNA levels of human NGF determined in the peri-infact zone 
at 3 days post-MI. Data are expressed as mean±SEM (n=5/group). **P<0.01 vs. 
MI/p.Null. 
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Figure 9.  NGF protein content after gene transfer 
Immediately after MI, the peri-infarct myocardium was injected with a plasmid carrying 
the human NGF gene (p.NGF) or an empty vector (p.Null). After 14 days, the NGF 
protein content was studied by immuno-histochemistry using an antibody which 
recognized both the murine and human NGF protein (Magnification 200x). 
 
 
NGF over-expression increases capillary density in 
the peri-infarct area 
 
Two weeks after myocardial infarction and p.Null or p.NGF 
gene delivery, capillary density was evaluated by Silver-
hexamethylenetetramine staining in 4µm-thick heart sections. The 
number of capillary per mm2 of tissue was similar in the remote zone 
of hearts harvested from p.Null- (3843±358 cap/mm2) or p.NGF-
injected mice (4313±407; P=N.S.). 
In contrast, capillary density was potentiated by p.NGF at the 
level of the injected peri-infarct zone (5131±242 cap/mm2) 
corresponding to a significant 1.57-fold increase vs. p.Null 
(3252±341; P<0.05) (Figure 10). 
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Figure 10.  Capillary density in the peri-infarct and remote myocardium 
following plasmid-mediated gene delivery 
Capillary density was investigated two weeks after myocardial infarction and p.NGF or 
p.Null gene delivery. The micro-photographs show heart sections after Silver staining 
(Magnification 200X). Bar graphs show capillary numerical density per mm2 of tissue in 
both remote and peri-infarct zones. The number of capillaries per mm2 was assessed 
following the analyses of twenty five fields at 1000X magnification. Data are presented 
as mean±SEM (n=5/group). *P<0.05 vs. MI/p.Null. 
 
 
Similar results were obtained when gene transfer to the mouse 
peri-infarct myocardium was mediated by adenoviral vectors and 
capillary density evaluated after fluorescent immuno-histochemical 
staining of endothelial cells for Factor VIII (Figure 11, green 
fluorescence) in heart sections. In the same sections, 
cardiomyocytes were stained for α-sarcomeric actin (red 
fluorescence) and nuclei counterstained with DAPI (blue 
fluorescence). As shown in Figure 11, Ad.NGF improved capillary 
density of the peri-infarct myocardium (5348±144 cap/mm2 vs 
4116±264 cap/mm2 for Ad.Null; P<0.05). 
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Figure 11.  Capillary density in the peri-infarct and remote myocardium 
following adenovirus-mediated gene transfer 
Capillary density two weeks after myocardial infarction and Ad.NGF or Ad.Null gene 
transfer was assessed following immuno-fluorescence staining for Factor VIII. The 
micro-photographs show capillary density in the peri-infarct zone of Ad.Null and 
Ad.NGF injected hearts. Capillaries are stained in green fluorescence, cardiomyocytes 
in red and nuclei in blue (Magnification 200X). Bar graphs show capillary numerical 
density per mm2 of tissue in the peri-infarct zone. Data are presented as mean±SEM 
(n=5/group). *P<0.05 vs. MI/Ad.Null. 
 
 
 
Collectively, these data indicate that NGF potentiates 
reparative angiogenesis in the area at risk. The improved capillary 
density in the peri-infarct area of NGF-treated animals suggests that 
the neurotrophin is able to stimulate therapeutic neovascularisation 
and reinforce the idea that neurotrophins are important for the 
cardiovascular system.  
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NGF over-expression reduces apoptosis of both 
endothelial cells and cardiomyocytes after myocardial 
infarction 
 
Intra-myocardial over-expression of NGF by either a plasmid or 
an adenoviral vector reduced apoptosis of both endothelial cells and 
cardiomyocytes in the peri-infarct area two weeks after MI.  
Apoptosis of CM was revealed by double staining for TUNEL 
and the cardiac marker α-sarcomeric actin. 
The TUNEL assay revealed a significant reduction of the 
number of apoptotic cardiomyocytes in the peri-infarct zone of 
p.NGF-injected MI hearts (66±8.2 apoptotic CM/mm2) compared 
with p.Null-injected hearts (93±5.7 apoptotic CM/mm2; P<0.05) 
(Figure 12). 
No significant group difference was detected in the remote 
zone (p.Null: 55±3.2 apoptotic CM/mm2; p.NGF: 47±4.5 apoptotic 
CM/mm2, P=N.S.).   
Similar data were obtained in experiments performed with 
adenoviral vectors. 
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Figure 12.  NGF reduces apoptosis of cardiomyocytes in vivo 
a.) Sections of the peri-infarct area of hearts harvested at 2 weeks post-MI were 
double stained for TUNEL and α-sarcomeric actin. Micro-photographs show the 
reduced number of apoptotic cardiomyocytes in the peri-infarct zone of p.NGF-
injected hearts. Arrows point to apoptotic myocytes (Magnification 200X). b.) Bar 
graphs show the number of apoptotic CM in both remote and peri-infarct area. Data 
are expressed in number of TUNEL positive cells per mm2. Data are presented as 
mean±SEM (n=5/group). *P<0.05 vs. MI/p.Null. 
 
 
 
Apoptotic endothelial cells were detected after TUNEL staining 
combined with the endothelial marker Factor VIII. The number of 
apoptotic cells was calculated for mm2. 
The number of apoptotic endothelial cells was significantly less 
in the peri-infarct zone of p.NGF treated mice (29±7.4 versus 48±5.7 
apoptotic endothelial cells/mm2 in p.Null; P<0.01; Figure 13). There 
were no differences in endothelial cells apoptosis in the remote zone 
between the groups (p.Null, 34±6.4 apoptotic endothelial cells/mm2; 
p.NGF, 27±3.5 apoptotic endothelial cells/mm2, P=N.S.).  
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Similar data were obtained in experiments performed with 
adenoviral vectors. 
 
 
Figure 13.  NGF reduces apoptosis of endothelial cells in vivo 
a.) Representative sections from the peri-infarct myocardium of p.Null and p.NGF 
transduced hearts harvested at 2 weeks post-MI. Sections were double stained for 
TUNEL and Factor VIII. Arrows point to apoptotic endothelial cells (Magnification 
200X). b.) Bar graphs show the number of apoptotic endothelial cells in both remote 
and peri-infarct area. Data are expressed in number of TUNEL positive cells per mm2. 
Data are presented as mean±SEM (n=5/group). *P<0.05 vs. MI/p.Null. 
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NGF over-expression increases the 
phosphorylation of eNOS and Akt in the infarcted heart 
 
NGF gene transfer resulted in an increased phosphorylation/ 
activation of the pro-angiogenic and anti-apoptotic factors Akt and 
eNOS.  
As shown in Figure 14, western blot analyses of heart protein 
extract three days after myocardial infarction showed that the ratio of 
phosphorylated to total Akt was higher in Ad.hNGF-injected MI 
hearts than in Ad.Null-injected MI hearts or Ad.Null-injected sham 
operated hearts (P<0.05 for both comparison). Moreover, Ad.hNGF 
also up-regulated the phosphorylation of eNOS in the peri-infarct 
zone compared to controls (P<0.05 for both comparison). 
 
Figure 14.  NGF gene transfer increases p-Akt and p-eNOS protein levels 
a.) Representative western blot of phospho-Akt (pAkt), total Akt, phospho-eNOS 
(peNOS) and total eNOS in the peri-infarct zone. Tubulin was used as loading control. 
b.) Bar graphs show the ratio between pAkt to total Akt (upper panel) and peNOS to 
total eNOS (lower panel) Data are presented as mean±SEM (n=5/group). §<0.05 vs 
sham-operated; *P<0.05 vs. MI/p.Null. 
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NGF over-expression does not change indexes of 
cardiac function 
 
The hemodynamic parameters, systolic LV pressure (LVP, 
mmHg), maximal rate of LV pressure rise (dP/dtmax, mmHg/s) and 
fall (dP/dtmin, mmHg/s) and heart rate (HR, bpm), were measured by 
the use of a Millar-Micro-Tip catheter at five weeks after MI, a time 
point in which cardiac dysfunction is generally evident. 
As shown in Table 3, either MI/p.Null- or MI/p.NGF-injected 
mice showed a deterioration of cardiac function in comparison to 
sham-operated, thus indicating that plasmid-mediated NGF gene 
transfer did not result in long-lasting positive effects on cardiac 
function. 
 
  
Sham/p.Null MI/p.Null MI/p.NGF 
- LVP (mmHg) 
- dP/dtmax 
(mmHg/s) 
- dP/dtmin 
(mmHg/s) 
- HR (bpm) 
87.6±2.3 
6078±278 
-5342±243 
429±19 
73.7±3.4 * 
4001±189 * 
-3175±128 * 
410±13 
70.2±3.9 * 
3986±212 * 
-3255±219 * 
432±16 
 
Table 3.  Cardiac function at five weeks after myocardial infarction 
Mice underwent MI or sham-operation. p.Null and p.NGF gene delivery was performed 
immediately after MI. Five weeks after MI, hemodynamic parameters were measured 
by using a Millar-Tip catheter inserted into the LV cavity. Each group consisted at least 
of n=12 mice. Values are in mean±SEM. *P<0.05 vs. sham. 
 
 
 
At the same time-point the heart remodeling was analysed. To 
this aim, the heart weight to body weight ratio (HW/BW), left 
ventricle weight to BW ratio (LVW/BW) and right ventricle to BW 
ratio (RVW/BW) were determined. Additionally, left ventricle free 
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wall thickness, left ventricle transversal diameter and chamber 
volume were also measured.  
Data are shown in Table 4. 
 
  
Sham/p.Null MI/p.Null MI/p.NGF  
- HW/BW (x1000) 5.39±0.5 5.63±1.2 6.02±0.7 * 
- LVW/BW 
(x1000) 3.78±0.4 3.94±0.5 4.16±0.2 * 
- RVW/BW 
(x1000) 1.21±0.3 1.30±0.3 1.26±0.5 
- LV free wall 
thickness (mm) 1.13±0.2 1.36±0.2 * 1.40±0.2 * 
- LV transversal 
diameter (mm) 3.94±0.7 3.91±1 3.44±0.5 * 
- LV chamber 
volume (mm3) 71.2±33.3 78.62±44.6 58.6±18.6 *§ 
 
Table 4.  Heart remodeling five weeks after myocardial infarction 
Five weeks after MI or sham-operation, the hearts of mice were perfused-fixed with 
formalin and stopped in diastole. The RV was separated from the LV and heart 
remodeling was measured. Each group consisted at least of n=12 mice. Values are in 
mean±SEM. *P<0.05 vs. sham; §P<0.05 vs. MI/p.Null. 
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Rat neonatal cardiomyocytes express TrkA and 
produce NGF 
 
The presence of TrkA on rat neonatal cardiomyocytes (RNCM) 
was determined by both RT-PCR and western blot. As shown in 
Figure 15, RNCM express TrkA at both mRNA and protein levels. 
NGF expression was also found by RT-PCR in RNCM-derived 
mRNA. PC12 cells, which express high level of TrkA, were used as 
reference. 
 
 
Figure 15.  RNCM express TrkA and NGF 
a.) RT-PCR demonstrates the presence of mRNA for TrkA and NGF in cultured rat 
neonatal cardiomyocytes (RNCM). Bands are representative of 3 experiments. 
Ribosomial RNA (18S) was used as a loading control. b.) Western blot analysis of TrkA 
in lysates of RNCM. PC12 protein extracts were loaded as positive controls for TrkA. 
Bands are representative of 3 experiments. 
 
 
 
 
 
 
 
 
a. b. 
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Furthermore, the ability of RNCM to produce NGF was also 
investigated by fluorescence double-staining for NGF and the 
cardiomyocyte marker α-sarcomeric actin. As shown in Figure 16, 
more than the 95% of cultured RNCM are stained for α-sarcomeric 
actin, and many of those cells are also positive for NGF. Importantly, 
NGF and α-sarcomeric actin co-localize, thus suggesting that 
cardiomyocytes can produce the neurotrophin. 
 
 
Figure 16.  NGF expression in RNCM by immuno-fluorescence 
Cultured RNCM were double-stained for the cardiac marker α-sarcomeric actin (in red 
fluorescence) and NGF (in green fluorescence). Nuclei were counterstained by DAPI 
(in blue). The co-localization of NGF and α-sarcomeric actin is evident in many cells 
and this indicates that cardiomyocytes produce NGF. 
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Moreover, in order to analyze whether NGF is secreted by 
cardiomyocytes, the presence of NGF in serum-free conditioned 
culture medium has also been investigated. By ELISA, we could 
demonstrate that RNCM produce NGF (Figure 17), which is 
functionally competent, since the serum-free culture medium of 
RNCM was able to promote neurite outgrowth from PC12 cells. 
Consistently, a neutralizing antibody for NGF prevented PC12 
differentiation (Figure 17). 
 
 
Figure 17.  RNCM-produced NGF is functionally competent 
a.) NGF content in the RNCM conditioned culture medium (CCM) and in basal culture 
medium (CM) was measured by ELISA. Data are presented as mean±SEM (n=3). 
**P<0.01 vs. CM.  
b.) RNCM-produced NGF stimulates the differentiation of PC12. PC12 morphology was 
observed after incubation for 3 days in the RNCM CCM or in CM. CCM induced neurite 
extension in PC12. A NGF neutralizing antibody (Ab-NGF) prevented PC12 
differentiation. Data are presented as mean±SEM (n=3). **P<0.01 vs. CM and §P<0.05 
vs. CCM. 
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NGF signaling in rat neonatal cardiomyocyes 
 
In order to study the impact of NGF on the PI3K/Akt survival 
pathway, serum-free cultured RNCM were stimulated with NGF 
(50ng/ml) for 10, 20, or 60 min. As shown in Figure 18, addition of 
NGF resulted in the phosphorylation of TrkA (Tyr-490, active form), 
Akt (Ser-473, active form), Foxo-3a (in Thr-32, inactive form), and 
Foxo-1 (in Ser-256, inactive form). The NGF-induced 
phosphorylation of TrkA and Akt peaked at 20 min and returned to 
the basal level by 60 min, whereas the phosphorylation of both 
Foxo-3a and Foxo-1 was maximal at 60 min. 
 
 
Figure 18.  NGF signaling in RNCM 
Serum-starved RNCM received NGF (50ng/ml). After 0, 10, 20, and 60 min, the 
phosphorylation of TrkA (Tyr-490), Akt (Ser-473), Foxo-3a (Thr-32) and Foxo-1 (Ser-
256) was determined by western blot. Tubulin was used as loading control. Graphs 
show the ratio between the densitometric reading of phosphorylated and total TrkA, 
Akt, Foxo-3a, and Foxo-1. Data are presented as mean±SEM (n=3). *P<0.05 vs. time 
zero.  
 
 
In separate experiments, 30 min before NGF, RNCM were pre-
treated with the TrkA inhibitor K252a (100nM), or with the PI3K 
inhibitor LY294002 (50µM), or vehicle (0.1% DMSO). As shown in 
Figure 19a, K252a totally prevented Akt phosphorylation, thus 
suggesting that TrkA mediates NGF-induced Akt activation.  
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Moreover, also LY294002 prevented the phosphorylation of 
Foxo-3a and Foxo-1 in response to NGF, thus suggesting that Foxo 
is downstream to Akt in the pathway initiated by NGF in RNCM 
(Figure 19b). 
 
 
Figure 19.  NGF signaling in RNCM 
a.) Serum-starved RNCM were pre-treated with the TrkA inhibitor K252a (100nM) or its 
vehicle (0.1% DMSO) before adding NGF. After 20 min, the phosphorylation of TrkA 
and Akt was examined. Controls (PBS) received 0.1% DMSO (instead of K252a) and 
PBS (instead of NGF). Tubulin was used as loading control. K252a blocked the 
phosphorylation of both TrkA and Akt. b.) Serum-starved RNMC were pre-treated with 
the PI3K inhibitor LY294002 (50nM) or its vehicle (0.1% DMSO) before adding NGF. 
After 20 min, the phosphorylation of Akt, Foxo-3a, and Foxo-1 was evaluated. Controls 
received 0.1% DMSO and PBS. Tubulin was used as loading control. LY294002 
blocked the phosphorylation of Akt, Foxo-3a, and Foxo-1. Graphs show the ratio 
between the densitometric reading of phosphorylated and total Akt, phosphorylated 
and total Foxo-3a, and phosphorylated and total Foxo-1. Data are presented as 
mean±SEM (n=3). *P<0.05 vs. PBS; §P<0.05 vs. NGF+0.1% DMSO (NGF). 
 
 
We finally investigated whether the same pathway is activated 
by cardiomyocyte-released NGF. To this aim, RNCM were treated 
with Ab-NGF or K252a (or the respective controls) for 48h in serum-
free medium. Cells were lysated to perform western blot analyses 
for phospho-Akt (Ser-473), phospo-Foxo-3a (Thr-32), phospho-
Foxo-1 (Ser-256), and for the respective total forms. As shown in 
Figure 20, both Ab-NGF and K252a impaired the phosporylation of 
Akt, Foxo-3A and Foxo-1. This strongly suggests that the 
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NGF/TrkA/Akt/Foxo pathway may physiologically regulate 
cardiomyocyte survival. 
 
 
Figure 20.  Endogenous NGF regulates phosphorilation of Akr and Foxo via 
TrkA 
Serum-free cultured RNCM were treated for 48h with Ab-NGF or K252a. Controls 
received 0.1% non-immune goat serum or 0.1% DMSO, respectively. Either Ab-NGF or 
K252a reduced phosphorylation of Akt, Foxo-3a, and Foxo-1. Tubulin was used as 
loading control. Graphs show the ratio between the densitometric reading of 
phosphorylated and total Akt, phosphorylated and total Foxo-3a, and phosphorylated 
and total Foxo-1. Data are presented as mean±SEM (n=3). *P<0.05 vs. 0.1% goat IgG 
(IgG); §§P<0.01 vs. 0.1% DMSO. 
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NGF over-expression prevents apoptosis of rat 
neonatal cardiomyocytes 
 
As shown in Figure 21, the number of apoptotic RNCM 
increased following hypoxia/reoxygenation (H/R). Importantly, 
Ad.NGF prevented H/R-induced RNCM apoptosis. The upper panels 
show typical images of RNCM stained for cleaved caspase-3 (green 
fluorescence). Nuclei are counterstained by DAPI (blue 
fluorescence).  
 
 
 
Figure 21.  NGF over-expression prevents apoptosis of RNCM 
RNCM were transduced with Ad.NGF or Ad.βGal, or not infected (PBS). After 24h, 
RNCM underwent 12h of hypoxia followed by 24h reoxygenation. Some RNCM were 
maintained under normoxia as control. Apoptotic RNCM were detected by cleaved 
caspase-3 staining (green fluorescence). Bar graph shows the quantitative analysis of 
apoptosis, expressed as percentage of cleaved caspase 3-positive RNCM. Data are 
presented as mean±SEM (n=3). *P<0.05 vs. PBS; §P<0.05 vs. Ad.βGal. 
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The pro-survival action of Ad.NGF after 
hypoxia/reoxygenation-induced apoptosis was confirmed by TUNEL 
assay (Figure 22).  
 
 
Figure 22.  NGF over-expression prevents apoptosis of RNCM after 
hypoxia/reoxygenation 
Apoptosis on RNCM transduced with Ad.NGF or Ad.βGal (PBS was used as control) 
and submitted to 12h hypoxia followed by 24h reoxygenation were also analyzed after 
TUNEL assay. In the representative images, TUNEL-positive RNCM are pointed by the 
arrows. Bar graph quantifies apoptosis, which is expressed as percentage of TUNEL-
positive RNCM.  Data are presented as mean±SEM (n=3). *P<0.05 vs. PBS; §P<0.05 
vs. Ad.βGal. 
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The anti-apoptotic action of Ad.NGF was also observed when 
apoptosis was induced by Angiotensin II (Figure 23). 
 
 
Figure 23.  NGF over-expression prevents Angiotensin II-induced apoptosis 
After transduction with Ad.NGF or Ad.βGal RNCM were submitted to Angiotensin II 
apoptotic assay. Apoptotic cells were detected by cleaved caspase-3 fluorescence 
staining (green fluorescence). Nuclei were revealed by DAPI (blue fluorescence). Bar 
graphs show the percentage of RNCM positive for caspase-3. Data are presented as 
mean±SEM (n=3). *P<0.05 vs. PBS; §P<0.05 vs. Ad.βGal. 
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NGF induces human EPC migration and 
proliferation 
 
 Human EPC migration towards NGF was determined by using 
a modified Boyden chamber. Figure 24 shows that NGF significantly 
increases the migration of EPC compared with control. No 
significantly differences were found considering the three doses of 
recombinant NGF.  
Those results show that human endothelial progenitor cell of 
peripheral blood origin migrate following exposure to an NGF 
gradient. 
 
 
Figure 24.  NGF induces EPC migration 
EPC migration following stimulation by NGF. Migration studies were conducted in a 
modified Boyden chamber incubating cells with NGF (10ng/ml, 50ng/ml and 100ng/ml), 
SDF-1 (100ng/ml) or control medium alone (CM). The fluorescence imaging panels 
show the DAPI positive cells after migration. EPC migration towards NGF is represented 
at the dose of 50ng/ml of NGF. The diagram shows the mean (± SEM) number of 
migrated cells counted in three independent experiments (n=3). **P<0.01 vs. CM. 
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To further elucidate the biological significance of NGF for 
endothelial progenitor cells, EPC proliferation in response to NGF 
has been analysed by an MTS colorimetric assay.  
NGF stimulation resulted in a promotion of EPC proliferation 
compared to control. As shown in Figure 25, the lowest dose of NGF 
(5ng/ml) induced a significant elevation of EPC viability compared to 
control medium, while NGF at higher doses did not result in an 
improvement of cells proliferation. 
 
 
 
 
 
Taken together, these data show that NGF is not only involved 
in angiogenic process but, since it is able to improve EPC migration 
and proliferation, can also have an impact on vasculogenesis.  
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Figure 25.  EPC 
proliferation is induced by 
NGF 
EPC proliferation was 
studied by MTS Assay. EPC 
were cultured for 24h with 
different doses of NGF 
(5ng/mL, 50ng/mL and 
100ng/mL).  
Control medium (CM) with 
10%FBS was used as 
positive control. Results are 
expressed in optical density, 
which was measured at 
490nm. *P<0.05 vs. CM. 
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Discussion 
 
 
Therapeutic angiogenesis is a promising strategy for the cure 
of ischemic heart diseases. The goal of this therapy is to build up 
sufficient vessels to compensate for decreased blood flow in 
ischemic tissues.  
Angiogenic therapy has been carried out in laboratory animals 
for more than a decade and a wealth of evidence has shown that 
several growth factors can induce neovascularisation in ischemic 
models.46, 47  
Furthermore, some controlled clinical studies have been 
carried out using angiogenic factors, especially VEGF-A.49, 112  
The most commonly used modalities for growth factors 
delivery are plasmids or adenoviral vectors.  Although the optimal 
application of growth factors and delivery method require further 
exploration, research in this field showed sufficient levels of safety 
and efficacy in the use of those vectors.43, 113 
 
Recent studies have demonstrated the angiogenic properties 
of neurotrophins, and in particular NGF57, 114 and BDNF.115, 116 
Although the functions of neurotrophins were initially considered to 
be limited at the central and peripheral nervous system, recent 
studies have revealed their potential for vascular biology.57, 58, 60 For 
instance, our group discovered that NGF is able to promote 
neovascularisation in a murine model of peripheral ischemia and 
diabetic skin wounds,57, 59, 60 describing the involvement of protein 
kinase B-Akt, VEGF-A and nitric oxide in NGF-induced 
angiogenesis.57 We also showed that NGF is able to protect 
endothelial cells and skeletal myocytes from apoptosis.59 
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Based on these data, the aim of my PhD studies was to 
evaluate the possible therapeutic effect of NGF in a mouse model of 
myocardial infarction. We investigated whether NGF induces 
reparative neovascularisation in MI, and promotes the survival of 
cardiomyocytes and endothelial cells. Finally, we also analyzed the 
impact of NGF on EPC migration and proliferation, two mechanisms 
which are relevant for vasculogenesis. 
 
Our study documents that local intra-myocardial NGF gene 
delivery in the peri-infarct zone immediately after myocardial 
infarction stimulates capillary growth and reduces apoptosis of 
endothelial cells and cardiomyocytes.  
Moreover, the pro-angiogenic and anti-apoptotic potential of 
NGF was associated with an increase in eNOS phosphorylation 
through the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. This 
observation is in line with previous findings of Cantarella et al.58 and 
our group,57 which indicated the activation of eNOS by Akt in 
response to NGF. Collectively, these data suggest that NGF is able 
to restore the balance between pro-survival and pro-apoptotic 
factors in the infarcted heart. 
These results reinforce the idea of a therapeutic potential of 
NGF, as improved neovascularisation may ameliorate the 
oxygenation of the infarcted myocardium, thus preventing further 
cardiomyocyte loss. Furthermore, we showed the up-regulation of 
the endogenous NGF and its TrkA receptor in the infarcted heart, 
and this is in agreement with what previously reported by Hiltunen et 
al.117 in a rat model of coronary ischemia/reperfusion and also with 
our results in ischemic hind-limb muscle.57 The finding that NGF 
expression level increases after myocardial infarction suggests that 
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this system may be involved in the spontaneous reparative 
responses developed by the infarcted heart. 
 
We also analyzed heart remodeling at five weeks post-
myocardial infarction after NGF gene delivery.  p.NGF reduced the 
left ventricle chamber volume, thus suggesting that NGF may 
prevent dilatation of the infarcted LV and, through this action, slow 
the progression versus heart failure. By contrast, indexes of cardiac 
function (measured by the Millar catheter system) were not different 
between groups.  
 
To better understand the pro-survival and anti-apoptotic 
features of NGF on the cardiomyocyte, we analysed its role in rat 
neonatal cardiomyocytes in vitro.  
Interestingly, neonatal cardiomyocytes express TrkA and 
release active NGF, which stimulates the phosphorylation of Akt 
leading to the phosphorylation and inactivation of Foxo-3a and 
Foxo-1 in the same cells, a result which is in accordance with the 
possibility that NGF may exert an autocrine control on 
cardiomyocyte survival. Moreover, the use of the TrkA inhibitor 
K252a or the PI3K inhibitor LY294002 could demonstrate the 
importance of TrkA and Akt in the regulation of the pro-survival and 
anti-apoptotic properties of NGF, thus strongly suggesting that the 
NGF/TrkA/Akt/Foxo pathway may physiologically control 
cardiomyocyte survival. 
Afterwards, the pro-survival action of NGF was also 
demonstrated in hypoxia/reoxygenation and Angiotensin II apoptosis 
assays. In RNCM, NGF over-expression after gene transfer showed 
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the capacity of the neurotrophin to combat apoptosis induced by 
those pro-apoptotic conditions.  
Taken together, these data indicate that NGF improved 
resistance of cardiomyocytes to pro-apoptotic stimuli. 
Additionally, the fact that NGF was active in cardiomyocytes 
from both rats and mice discards the possibility that the observed 
actions are species-specific, thus raising hope that NGF may be 
also useful for combating human cardiac diseases. 
 
Finally, since bone marrow-derived EPC have been shown to 
regenerate the myocardium by enhancing neovascularisation, we 
also investigated the influence of recombinant NGF on cultured EPC 
migration and proliferation. Adult bone marrow is a rich reservoir for 
endothelial and hematopoietic stem and progenitor cells that 
contribute to revascularization of injured tissue. 
Many experimental studies proved that vascular regeneration 
and angiogenesis require migration of various cells, and that both 
migration and proliferation of endothelial cells and EPC, among 
many other factors, contribute to angiogenesis. 
 
We found that both migration and proliferation of EPC were 
improved after NGF stimulation, thus suggesting that NGF may be 
able to promote the expansion of EPC and their mobilization and 
homing to ischemic tissues, thus ultimately favouring the hypothesis 
that NGF may positively impact on vasculogenesis.  
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In conclusion, our results suggest that intra-myocardial NGF 
induces reparative neovascularisation by promoting both 
angiogenesis and vasculogenesis and by inhibiting the apoptotic 
death of resident endothelial cells.  
In perspective, NGF may represent a potential tool to induce 
therapeutic angiogenesis in the setting of myocardial infarction. 
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